Summary 1 discusses the development and testing of Nanocovax, a COVID-19 vaccine candidate using the SARS-CoV-2 spike protein. It highlights the vaccine's effectiveness in producing specific immune responses in various animal models, its protective effects in viral challenge studies, and its safety profile across different species. Summary 2 focuses on Niclosamide, an existing drug with potential antiviral activity against SARS-CoV-2, but its use for COVID-19 treatment is complicated by issues like low bioavailability and high cytotoxicity. While it shows some antiviral properties, its side effects limit its applicability, prompting exploration of safer analogs. Summary 3 evaluates the impact of extended intervals between doses of the Pfizer-BioNTech COVID-19 vaccine in healthcare workers. It indicates that prolonging the interval improved antibody responses compared to the standard timeline, sustaining T cell immunity and providing robust protection, suggesting alternative dosing strategies for effective vaccination.